Numinus Clarifies Disclosures
On June 7, 2024, Numinus Wellness clarified disclosures from two previous press releases dated May 30, 2024. The first release discussed Numinus' participation in Cybin's Phase 3 trials for major depressive disorder, led by Cedar Clinical Research in Murray, Utah. However, Numinus clarified it has no ownership in CYB003, and results will be shared by Cybin at their discretion. The second release covered Numinus' plans for a new community pilot and Numinus Network, targeting therapists and practitioners. Numinus emphasized that this initiative does not offer access to medical infrastructure for psychedelic therapies and that the subscription model's rollout is uncertain. Both releases included forward-looking statements subject to risks and uncertainties.
- Cedar Clinical Research engaged by Cybin Inc. for Phase 3 trial of CYB003.
- Numinus Network community pilot planned for therapists and practitioners.
- Collaboration planned between Numinus and the Canadian Centre for Psychedelic Healing on training content.
- No direct or indirect ownership interest in CYB003 by Numinus.
- Results from CYB003 research are under Cybin's control and may not be shared.
- Numinus Network will not provide access to medical infrastructure for psychedelic therapies.
- Uncertainty around the rollout of the subscription-based model in Canada and the U.S.
- Forward-looking statements subject to risks and uncertainties.
Vancouver, British Columbia--(Newsfile Corp. - June 7, 2024) - Numinus Wellness Inc. (TSX: NUMI) (OTCQX: NUMIF) ("Numinus" or the "Company"), a mental health care company advancing traditional and innovative behavioral health treatments with a focus on safe, evidence-based psychedelic-assisted therapies, wishes to clarify two news releases disseminated on May 30, 2024, titled "Numinus and Cybin Embark on a Groundbreaking Journey: Pioneering Phase 3 Trials for Major Depressive Disorder" ("Release 1") and "Numinus Wellness Charts Path To Profitability While Strengthening Community Ties" ("Release 2" and, together with Release 1, collectively, the "Releases").
The Releases were inadvertently disseminated by a public relations firm contracted by the Company and represent information that was previously disseminated by the Company. The Company apologizes for any confusion.
Release 1
The Company confirms that Cedar Clinical Research ("CCR"), has been engaged by Cybin Inc. ("Cybin") to provide clinical research services and that its Murray, Utah, location will be one of 15 U.S. research sites for Cybin's Phase 3 multinational clinical trial of CYB003. However, Dr. Paul Thielking is the Site Principal Investigator for the CCR site, and he is not the trial's Principal Investigator. Numinus has no direct or indirect ownership interest in CYB003. As such, results of any CYB003 research are the property of its sponsor, Cybin, and findings would be shared by Cybin if, as and when Cybin deems appropriate.
Please refer to the Company's news release dated April 17, 2024, and titled "Cedar Clinical Research selected as clinical research site for Cybin's Phase 3 Study of CYB003" for details regarding the Company's role in CYB003 (the "CYB003 Release").
Release 2
The Company confirms that it plans to launch a Numinus Network community pilot, which will be made available to its current therapists and other practitioners, alumni of its training program, and former therapists and other practitioners, including those who join the Canadian Centre for Psychedelic Healing ("CCPH") when it is launched. In addition to training, the Numinus Network provides access to Numinus treatment protocols, promotional support, and access to Numinus' extensive network of experienced health care professionals. However, the planned community pilot program and Numinus Network do not provide access to medical infrastructure for the therapeutic administration of ketamine and other psychedelic drugs within Canada's regulatory framework, which may be through a program such as CCPH's co-op program. Further, there can be no assurance that a subscription-based model of the Numinus Network will be rolled out in Canada and/or the U.S.
The Company further confirms that it and CCPH have agreed in principle to collaborate on the development of training content for the Numinus learning platform. However, the terms of this collaboration shall be mutually agreed in a subsequent agreement.
Please refer to the Company's news release dated April 15, 2024, and titled "Numinus Wellness Provides Corporate Update" for further details (the "Update Release").
Important Information regarding the Releases
The Releases included statements that are future oriented information concerning our plans, intentions, and expectations, which are not historical in nature. Such statements are subject to risks and uncertainties and there can be no assurance that those plans, intentions, and/or expectations will occur. Please refer to the CYB003 Release for disclosures concerning forward-looking statements in Release 1 and refer to the statement below under the heading "Forward-looking statements" as well as Update Release for disclosures concerning forward-looking statements in Release 2.
About Numinus
Numinus Wellness Inc. (TSX: NUMI) helps people to heal and be well through the development and delivery of innovative mental health care and access to safe, evidence-based psychedelic-assisted therapies. The Numinus model - including psychedelic research, clinic care and practitioner training - is at the forefront of a transformation aimed at healing rather than managing symptoms for depression, anxiety, trauma, pain, and substance use. At Numinus, we are leading the integration of psychedelic-assisted therapies into mainstream clinical practice and building the foundation for a healthier society.
Learn more at www.numinus.com and follow us on LinkedIn, Facebook, Twitter, and Instagram.
SOURCE Numinus Wellness Inc.
Forward-looking statements
Statements and other information contained in this press release about anticipated future events constitute forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "seek", "anticipate", "believe", "plan", "estimate", "expect" and "intend" and statements that an event "may", "will", "should", "could" or "might" occur or other similar expressions. Forward-looking statements are subject to risks and uncertainties and other factors that could cause actual results to differ materially from those contained in the forward-looking statements, including the successful launch and commercialization of the Numinus Network, uptake of the Numinus Network offering by practitioners, commercial viability of any or all of the Numinus Network members, availability or continued availability of the services to be delivered to Numinus Network members, client uptake of services from members of the Numinus Network; disclosures concerning forward-looking statements in the Releases; and other risks that are set forth in our annual information form dated November 29, 2023 and available on SEDAR at www.sedarplus.ca. Forward-looking statements are based on estimates and opinions of management at the date the statements are made. Numinus does not undertake any obligation to update forward-looking statements even if circumstances or management's estimates or opinions should change except as required by applicable laws. Investors should not place undue reliance on forward-looking statements.
For more information:
Numinus
Investor Contact: Craig MacPhail invest@numinus.com
-30-
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/212078
FAQ
What is Numinus' role in Cybin's Phase 3 trials for major depressive disorder?
Does Numinus own CYB003?
What does the Numinus Network community pilot offer?
Will the Numinus Network offer medical infrastructure for psychedelic therapies?
Is the subscription-based model of the Numinus Network confirmed?
